Health care systems across the globe are as dynamic and complex as the populations they serve. Yet as varied as they are, they encounter common challenges as they strive toward the same goal — establishing and maintaining effective, affordable health care for their constituents. Last month, global experts and stakeholders convened to address some of […]
Read More »
Life sciences researchers, thought leaders and industry colleagues gathered in Singapore in early September to discuss the status of pharmacoeconomics and outcomes research in the Asia-Pacific region. The 7th ISPOR Asia-Pacific conference presented an opportunity to concentrate on the issues particular to this unique and diverse part of the world in an effort to achieve […]
Read More »
The Centers for Medicare & Medicaid Services’ (CMS) has implemented a five-star rating system for MedicareAdvantage and Part D health plans including measures of patient medication adherence for diabetes, hypertension and hypercholesterolemia. At the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting, my colleagues and I discussed how these new adherence requirements […]
Read More »
In a previous post by my colleague Dr. Aylin Altan Riedel, she presented an overview of Analyze This!, an educational symposium sponsored by Optum Life Sciences at the 18th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting. I’m pleased to be a part of this panel discussion focused on getting the […]
Read More »
Each year at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting, the Optum Life Sciences group hosts an educational symposium before the attending global researchers and thought leaders. At this year’s 18th ISPOR gathering, I’m pleased to moderate an important educational symposium to be held tomorrow titled, “Analyze This! Getting the […]
Read More »
